Retrospective Analysis of the Safety of High-Volume Dental Articaine Preparations for Japanese Patients.

IF 0.6 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Shigeru Maeda, Atiphan Pimkhaokham, Michihiro Yoshida, Hiroki Hosoi, Ayako Ohshima, Ryoko Kurisu, Nozomi Utsumi, Hitoshi Higuchi, Takuya Miyawaki
{"title":"Retrospective Analysis of the Safety of High-Volume Dental Articaine Preparations for Japanese Patients.","authors":"Shigeru Maeda, Atiphan Pimkhaokham, Michihiro Yoshida, Hiroki Hosoi, Ayako Ohshima, Ryoko Kurisu, Nozomi Utsumi, Hitoshi Higuchi, Takuya Miyawaki","doi":"10.18926/AMO/68356","DOIUrl":null,"url":null,"abstract":"<p><p>We retrospectively analyzed the safety of the use of articaine, an amide-type local anesthetic, in Japanese dental patients (n=300) treated in Thailand in 2015-2017. The dosage, adverse events (AEs) caused by local anesthesia, and treatment efficacy were examined. Articaine, which is safe for patients with liver impairments due to its unique metabolism, has not been thoroughly tested in Japan for doses above 5.1 mL. Eighty of the present patients had undergone root canal treatment (RCT), 71 underwent tooth extraction, and 149 underwent implant-related surgery. More than three articaine cartridges were used in 41 patients, and no AEs occurred in these cases. The only AE occurred in a 52-year-old woman who was treated with three cartridges and presented with what appeared to be hyperventilation syndrome; she later recovered and received her dental treatment as scheduled. Most treatments were completed with three or fewer cartridges, suggesting that this number is generally sufficient. Our findings, particularly the low AE risk even with doses exceeding three cartridges, support the potential applicability of the overseas recommended maximum dose of articaine (7 mg/kg) in Japanese patients. This conclusion is significant for advancing dental anesthetic practices and ensuring patient safety and treatment efficacy in Japan.</p>","PeriodicalId":7017,"journal":{"name":"Acta medica Okayama","volume":"79 1","pages":"31-37"},"PeriodicalIF":0.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Okayama","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18926/AMO/68356","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

We retrospectively analyzed the safety of the use of articaine, an amide-type local anesthetic, in Japanese dental patients (n=300) treated in Thailand in 2015-2017. The dosage, adverse events (AEs) caused by local anesthesia, and treatment efficacy were examined. Articaine, which is safe for patients with liver impairments due to its unique metabolism, has not been thoroughly tested in Japan for doses above 5.1 mL. Eighty of the present patients had undergone root canal treatment (RCT), 71 underwent tooth extraction, and 149 underwent implant-related surgery. More than three articaine cartridges were used in 41 patients, and no AEs occurred in these cases. The only AE occurred in a 52-year-old woman who was treated with three cartridges and presented with what appeared to be hyperventilation syndrome; she later recovered and received her dental treatment as scheduled. Most treatments were completed with three or fewer cartridges, suggesting that this number is generally sufficient. Our findings, particularly the low AE risk even with doses exceeding three cartridges, support the potential applicability of the overseas recommended maximum dose of articaine (7 mg/kg) in Japanese patients. This conclusion is significant for advancing dental anesthetic practices and ensuring patient safety and treatment efficacy in Japan.

日本患者大剂量牙科关节碱制剂安全性的回顾性分析。
我们回顾性分析了2015-2017年在泰国治疗的日本牙科患者(n=300)使用阿替卡因(一种酰胺型局麻药)的安全性。观察剂量、局部麻醉不良事件(ae)及治疗效果。阿替卡因由于其独特的代谢特性,对肝损伤患者是安全的,但在日本,对于超过5.1 mL的剂量,尚未进行彻底的测试。目前的患者中有80人接受了根管治疗(RCT), 71人接受了拔牙,149人接受了种植相关手术。41例患者使用了3个以上的阿卡因药筒,均未发生不良反应。唯一的AE发生在一名52岁的女性身上,她接受了三个氧气筒的治疗,并表现出过度通气综合征;她后来康复了,并如期接受了牙科治疗。大多数治疗是用三个或更少的药筒完成的,这表明这个数量通常是足够的。我们的研究结果,特别是即使剂量超过三盒也有较低的AE风险,支持了国外推荐的阿替卡因最大剂量(7mg /kg)在日本患者中的潜在适用性。这一结论对于推进日本牙科麻醉实践,确保患者安全和治疗效果具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta medica Okayama
Acta medica Okayama 医学-医学:研究与实验
CiteScore
1.00
自引率
0.00%
发文量
110
审稿时长
6-12 weeks
期刊介绍: Acta Medica Okayama (AMO) publishes papers relating to all areas of basic and clinical medical science. Papers may be submitted by those not affiliated with Okayama University. Only original papers which have not been published or submitted elsewhere and timely review articles should be submitted. Original papers may be Full-length Articles or Short Communications. Case Reports are considered if they describe significant and substantial new findings. Preliminary observations are not accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信